Bilastine And Montelukast Sodium Tablet Manufacturers In India

If you are searching for a trusted Bilastine and Montelukast Sodium tablet manufacturer in India, let us cut straight to the point. At Biotic Healthcare, we manufacture this high-demand anti-allergic combination under our flagship brand Bilagud-M — and we back it with WHO-GMP certified production, complete documentation support, and flexible commercial arrangements for PCD franchise partners, third-party clients, and bulk distributors. This blog covers the full picture: the molecule science, the market opportunity, our capabilities, the business case, and how you can get started. Read through and you will know exactly why more pharma entrepreneurs are choosing us as their manufacturing backbone.

Understanding the Bilastine + Montelukast Sodium Combination: Science, Market, and Commercial Relevance

Before we talk numbers and partnerships, let us build the foundation. The commercial strength of any pharma product starts with its clinical logic — and this combination has both in abundance. Bilastine is a second-generation, selective H1-receptor antihistamine. Unlike first-generation molecules like Chlorpheniramine or even early second-gen options like Cetirizine, Bilastine does not cross the blood-brain barrier effectively, which means it delivers powerful anti-allergic action without the sedation that has historically made antihistamines unpopular among working professionals and students. Montelukast Sodium, on the other hand, works through a completely different pathway — it selectively blocks leukotriene receptors (CysLT1), shutting down the inflammatory cascade that causes nasal swelling, bronchoconstriction, and prolonged allergic reactions. When you combine both molecules in a single tablet, you get antihistaminic suppression plus anti-inflammatory modulation — a dual-pathway approach that physicians across ENT, pulmonology, and general practice actively prefer over monotherapy.

How These Two Molecules Work Together — and Why That Matters Commercially

Here is the clinical logic translated into commercial value. Allergic responses involve two distinct phases: the immediate phase driven by histamine release (itching, sneezing, watery eyes) and the late phase driven by leukotriene-mediated inflammation (nasal congestion, airway swelling, persistent symptoms). Most single-molecule products handle one phase. Bilastine + Montelukast handles both. This means:

• Patients get faster symptom relief and longer-lasting control in a single dose
• Physicians get better compliance outcomes, which reinforces their prescribing habit
• You, as a distributor or franchisee, benefit from consistent prescription pull rather than episodic demand
• The non-sedating profile of Bilastine is a genuine selling point at the doctor and patient level — physicians mention it when prescribing, and patients appreciate it when they experience it
• Combination tablets also offer convenience (one tablet vs two), which improves patient adherence and reduces the chance of a patient switching to a generic antihistamine alone

Bilastine vs Older Antihistamines: Why the Market Is Shifting

If you are evaluating this product against older molecules that already dominate your portfolio, here is an objective comparison that will help you make the business case to doctors and chemists:

Therapeutic Indications That Drive Consistent Prescription Volume

This is not a product tied to one specialty or one season. Here is where Bilagud-M finds its prescription base:

• Perennial and seasonal allergic rhinitis — the single largest indication, with urban air quality issues making this a year-round prescription category
• Chronic and acute urticaria — dermatologists and general physicians actively prefer combination anti-allergics for chronic skin allergy cases
• Allergic asthma with rhinitis overlap — Montelukast's bronchodilatory support makes this combination a preferred adjunct in respiratory OPDs
• Post-viral allergic sensitivity — increasingly prescribed in post-COVID allergy cases involving nasal hyperreactivity
• Atopic dermatitis with systemic allergic involvement
• Paediatric-transitioning patients (adolescents shifting to adult dosing) where Bilastine's clean safety profile is advantageous

Explore our full tablet product section to see the complete anti-allergic and respiratory range we support.

The Indian Anti-Allergic Pharmaceutical Market: Why This Is the Right Category to Enter Right Now

We will give you the context that most manufacturers skip. The Indian allergy therapeutics market is one of the fastest-growing segments in domestic pharma — driven by rising urban pollution, changing climate patterns, increased diagnostic penetration in tier-2 and tier-3 cities, and growing awareness among patients about long-term allergy management versus one-time symptomatic relief. For a franchise partner or distributor entering this space, that market dynamic translates directly into sustainable demand.

Key Market Factors Working in Your Favour

• Urban Air Quality Crisis — India's major cities consistently rank among the most polluted globally. This is a direct driver of allergic rhinitis and airway sensitivity at a population level, and it is not a problem that resolves in the near term — which means your product is not riding a temporary trend
• Year-Round Demand Cycle — Unlike seasonal European allergy markets, Indian allergy seasons (dust, crop burning, humidity-driven mould) overlap in ways that keep anti-allergic prescriptions active through all four quarters
• Rapid Pharma Penetration in Tier-2 and Tier-3 Cities — ENT clinics, respiratory specialists, and general practitioners in smaller cities are now actively prescribing combination anti-allergics rather than older monotherapy, opening geographic markets that were previously underserved
• Shift Toward Branded Generics — Physicians and patients increasingly prefer quality-certified branded products over unbranded generics, which strengthens your position as a PCD partner carrying a reliable manufacturer's brand
• Digital Health Awareness — Patients researching their symptoms online are identifying allergy more specifically, arriving at clinics with clearer complaints, and driving more targeted prescriptions for combination anti-allergics
• Regulatory Clarity on the Combination — Bilastine + Montelukast is a CDSCO-cleared combination with Schedule H classification, which means no ambiguity around licensing or retail sales compliance for your chemist network

Product Composition and Packaging Specifications

Why Biotic Healthcare Is the Manufacturing Partner You Should Be Talking to First

We have been in this business long enough to know that most franchise partners and third-party clients do not just want a manufacturer — they want a partner who helps them build a business. That is the operating philosophy at Biotic Healthcare. Our manufacturing infrastructure, documentation systems, and partner support framework are all built with one goal: making your pharma business run smoother, faster, and more profitably. Here is what that looks like in practice.

Manufacturing Infrastructure and Quality Standards

Our facility operates under WHO-GMP certification with multi-shift production capacity across multiple dosage forms. For the Bilastine + Montelukast combination specifically, we have optimised the formulation for bioavailability consistency — critical for a molecule like Bilastine that depends on correct absorption timing for its 24-hour action window. Here is what our manufacturing commitment includes:

• GMP-Compliant Production Environment — Controlled temperature, humidity, and cleanroom standards maintained at every production stage
• Granulation and Coating Precision — Film coating applied for taste masking, moisture protection, and professional presentation at the chemist counter
• In-House QC Testing — Dissolution testing, assay, disintegration, and microbiological checks on every batch before release
• Batch Documentation — Batch manufacturing records, in-process quality checks, and finished goods testing reports maintained for every production run
• Alu-Alu Packaging Technology — Cold-formed Alu-Alu blister provides a superior moisture and light barrier compared to standard PVC blister — critical for maintaining tablet integrity in high-humidity Indian storage conditions
• Regulatory Documentation Package — COA, GMP certificate, stability data, MSDS, and product-specific dossier provided to every partner as standard
• Pharmacovigilance Support — We maintain ADR reporting systems in compliance with CDSCO requirements, giving you a cleaner compliance trail as a distributor

Bilastine + Montelukast Sodium Tablet Pricing in India: Location-Based Comparison

Pricing for Bilastine + Montelukast Sodium tablets is not uniform across India — and if you are evaluating this product for your franchise or distribution business, understanding the regional pricing structure will directly impact your margin planning. At Biotic Healthcare, our ex-factory pricing for Bilagud-M is consistent nationwide, but trade margins, MRP realisation, and competitive pricing pressure vary significantly by geography. Here is a breakdown that helps you plan before you commit.

Zone-Wise Indicative Pricing Structure for Bilastine + Montelukast 10×10 Alu-Alu Pack

The table below reflects the general market pricing landscape across Indian zones for this combination. These are indicative market figures — for our exact ex-factory pricing and your location-specific trade terms.

Metro vs Tier-2 vs Tier-3 Market: Where Your Margins Actually Sit

Geography is only half the picture. The type of market within your zone matters just as much — a metro city and a Tier-3 town in the same state can have completely different pricing dynamics, competition intensity, and margin structures. Here is how the three market tiers compare for this combination:

If you are entering this category fresh, Tier-2 and Tier-3 markets offer the strongest combination of manageable competition, healthy margins, and genuine prescription growth potential. 

Competitive Pricing Landscape: How Bilagud-M Positions Against Market Brands

Here is where we want to give you an honest picture. The Bilastine + Montelukast Sodium combination has several brands active in the Indian market across price segments. Understanding where Bilagud-M sits helps you position the product correctly with doctors and chemists in your territory.

Bilagud-M competes in the premium Indian generic segment — a deliberate positioning that gives you WHO-GMP quality and strong documentation at a price point significantly below MNC brands, while still delivering margins that make business sense. For your chemist network, the Alu-Alu packaging and branded presentation create shelf confidence that generic or budget products cannot match. For your doctor targets, our product documentation and manufacturing credentials hold up to scrutiny in any clinic or hospital setting.

State-Wise Demand and Pricing Priority: Where to Focus First

If you are deciding which geography to launch in, here is how we would prioritise — based on anti-allergic prescription density, franchise territory availability, and pricing power in the market:

To check territory availability in your specific district or state and get our confirmed ex-factory pricing and margin structure, All pricing enquiries are handled confidentially and responded to within 24 business hours.

Manufacturing Capabilities at a Glance

Promotional and Commercial Support We Extend to Partners

One thing that separates us from manufacturers who only handle production is the support structure we extend after the order is placed. If you are joining our PCD pharma franchise network, here is what comes with your Bilagud-M franchise:

• Branded visual aids and product detailing cards for doctor-level promotion
• MR bags, pens, notepads, and other chemist and doctor gifting inputs
• Product-specific catch covers and prescription pads
• Digital marketing creatives for WhatsApp, social media, and local digital promotion
• Monopoly territory agreement to protect your geographic exclusivity
• Dedicated relationship manager from our end for order, query, and escalation handling
• Guidance on doctor targeting by specialty for maximum prescription traction in your area

Business Models We Support — Find Where You Fit

We work across multiple pharma business formats. Our current partner base spans a wide range of business sizes and commercial structures:

• PCD Franchise Partners — Individuals or small businesses seeking monopoly-based distribution rights in a defined district or state, with full promotional input support and exclusive territory protection
• Third-Party / Contract Manufacturers — Companies launching or expanding their own brand in the anti-allergic segment using our WHO-GMP facility, formulation, and compliance infrastructure under their label
• Regional C&F Agents and Super Stockists — Established distribution businesses looking to add a premium branded anti-allergic to their existing portfolio with minimal setup effort
• Institutional Procurement Buyers — Hospital chains, polyclinics, or healthcare networks requiring reliable bulk supply at negotiated rates with consistent batch documentation
• Export-Oriented Businesses — Companies sourcing WHO-GMP certified Indian generics for regulated and semi-regulated markets across Asia, Africa, and Southeast Asia

Browse the full range on our pharma products catalogue or visit the Biotic Healthcare blog for detailed guides on building a pharma franchise business. When you are ready, our team is one click away on the contact page.

Frequently Asked Questions

Q. What is the exact composition of Bilagud-M and what conditions is it prescribed for?

Bilagud-M is a film-coated tablet containing Bilastine 20mg and Montelukast Sodium 10mg. It is primarily prescribed for seasonal and perennial allergic rhinitis, chronic urticaria, and as an adjunct in mild-to-moderate allergic asthma. The non-sedating nature of Bilastine makes it suitable for daytime use in working adults. You can review full product details on our Bilagud-M product page.

Q. Is Biotic Healthcare a WHO-GMP certified manufacturer for Bilastine Montelukast tablets?

Yes, we are. All tablets manufactured at our facility — including Bilagud-M — are produced under WHO-GMP and ISO certified conditions. We maintain complete batch documentation, in-house QC test reports, and regulatory certificates made available to every partner. You can also learn more about our background on the About Us page.

Q. Can I get monopoly PCD franchise rights for Bilagud-M in my district or state?

Yes. We offer exclusive monopoly territory rights to our PCD pharma franchise partners for Bilagud-M and our complete product portfolio. Territory allocation is based on current availability by district and state. We recommend checking early — states like Punjab, Haryana, Rajasthan, Uttar Pradesh, and Maharashtra see high demand in this category and zones fill quickly.

Q. Do you offer third-party manufacturing of Bilastine + Montelukast tablets under a custom brand name?

Absolutely. Our third-party manufacturing division handles complete white-label production for this combination. You provide your brand name and label artwork — we handle formulation, manufacturing, in-process testing, packaging, and dispatch, with full documentation including batch COA and GMP certificates under your brand name.

Q. What is the minimum order quantity for Bilagud-M under the PCD or TPM model?

Our MOQ varies based on the commercial arrangement — PCD franchise partners typically have lower entry-level quantities, while third-party and bulk clients work with higher volumes at better pricing. Please contact our team directly with your requirement and scale — we respond to all serious queries within 24 business hours.

Q. What schedule does Bilastine + Montelukast fall under, and does it affect chemist sales?

Bilastine + Montelukast Sodium is classified under Schedule H in India and requires a valid prescription from a registered medical practitioner for retail dispensing. For your distribution business, this is actually an advantage — Schedule H status keeps the product within the prescription channel, protecting it from over-the-counter price pressure and ensuring your chemist network maintains proper margins and documentation compliance.

Q. How does Biotic Healthcare support new franchise partners entering the anti-allergic segment for the first time?

We extend full commercial and promotional support to new PCD partners, including visual aids, product detailing cards, doctor gifting inputs, digital marketing creatives, and dedicated account management. Our team also guides you on the right doctor targeting strategy — which specialties to approach, how to position Bilagud-M against competitor brands, and how to build a consistent prescription base in your territory from day one.

Q. Where can I view Biotic Healthcare's full product range and contact the team?

Our complete portfolio is available on the pharma products page, with the tablet section for focused browsing. We also publish pharma business insights and product updates regularly on our blog. To speak with our commercial team, visit the contact page.

About Biotic Healthcare: We are a WHO-GMP certified pharmaceutical manufacturer and PCD pharma company based in India, serving franchise partners, third-party manufacturing clients, and institutional buyers across the country. To learn more about us, visit our About Us page.